EMA/709041/2022

European Medicines Agency decision

P/0379/2022

of 27 September 2022

on the acceptance of a modification of an agreed paediatric investigation plan for plasma kallikrein inhibitor (EMEA-002723-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0379/2022

of 27 September 2022

on the acceptance of a modification of an agreed paediatric investigation plan for plasma kallikrein inhibitor (EMEA-002723-PIP01-19-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0416/2020 issued on 23 October 2020,

Having regard to the application submitted by KalVista Pharmaceuticals Ltd on 14 April 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 July 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for plasma kallikrein inhibitor, film-coated tablet, age-appropriate oral solid dosage form, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to KalVista Pharmaceuticals Ltd, Porton Science Park, Bybrook Road, Porton Down, SP4 0BF – Salisbury, United Kingdom.

EMA/PDCO/261300/2022 Corr
Amsterdam, 22 July 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002723-PIP01-19-M01

Scope of the application

Active substance(s):

Plasma kallikrein inhibitor

Condition(s):

Treatment of hereditary angioedema

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

KalVista Pharmaceuticals Ltd

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, KalVista Pharmaceuticals Ltd submitted to the European Medicines Agency on 14 April 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0416/2020 issued on 23 October 2020.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 23 May 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of hereditary angioedema

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- film-coated tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of hereditary angioedema

2.1.1. Indication(s) targeted by the PIP

Treatment of hereditary angioedema in adolescents and children from 2 years of age

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	**Description**
Quality-related studies	**Study 1** Development of an age-appropriate oral solid dosage form for children from 2 to less than 12 years of age
Non-clinical studies	Not applicable
Clinical studies	**Study 2** (KVD900-301) Double blind, randomised, placebo-controlled, 3-way crossover trial to evaluate the efficacy and safety of two dose levels of KVD900 in adolescents from 12 to less than 18 years of age (and adults) with hereditary angioedema (HAE)

	Study 3 (KVD900-302) Open-label extension trial to evaluate long-term safety of KVD900 in adolescents from 12 to less than 18 years of age (and adults) with hereditary angioedema (HAE), including a PK sub-trial in adolescents **Study 4** (KVD900-303) Open-label trial to evaluate PK and safety of KVD900 in children from 2 to less than 12 years of age with hereditary angioedema (HAE)
Extrapolation, modelling and simulation studies	**Study 5** (3244-007) Population PK model **Study 6** (KVD900 Extrapolation) Analysis of existing in house and literature data on KVD900 on hereditary angioedema (HAE) in order to provide efficacy assumptions in the paediatric population from 2 to less than 12 years based on extrapolation from adults and adolescents
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By July 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes